More than half of patients with psoriasis have almost completely eliminated skin symptoms. The first TYK2 inhibitor is about to come out?

Today, Bristol-Myers Squibb (BMS) announced that the US FDA has accepted a new drug application (NDA) for the potential "first-in-class" oral selective TYK2 inhibitor deucravacitinib, and the European Medicines Agency (EMA) has also accepted deucravacitinib.

Psoriasis, also known as psoriasis, is a widespread chronic systemic immune-mediated disease that affects at least 100 million people worldwide

TYK2 is a member of the JAK family and is an intracellular signal kinase that mediates the signal transduction of IL-23, IL-12 and type I interferon (IFN)

▲Deucravacitinib has a unique mechanism of action (picture source: Bristol-Myers Squibb official website)

This regulatory application is based on the positive results obtained from 2 key phase 3 clinical trials

Reference materials:

[1] Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by US Food and Drug Administration and Validated by European Medicines Agency.

(The original text has been deleted)